Lanean...

Rimonabant for Neurocognition in Schizophrenia: A 16-Week Double Blind Randomized Placebo Controlled Trial

OBJECTIVE: To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia. METHODS: Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study. RESULTS: In comparis...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Boggs, Douglas L., Kelly, Deanna L., McMahon, Robert P., Gold, James M., Gorelick, David A., Linthicum, Jared, Conley, Robert R., Liu, Fang, Waltz, James, Huestis, Marilyn A., Buchanan, Robert W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3268840/
https://ncbi.nlm.nih.gov/pubmed/22137462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.schres.2011.11.009
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!